{"id":29537,"date":"2019-04-15T16:26:38","date_gmt":"2019-04-15T16:26:38","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=29537"},"modified":"2019-04-15T16:26:38","modified_gmt":"2019-04-15T16:26:38","slug":"canagliflozin-protects-heart-and-kidneys-credence-trial","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/","title":{"rendered":"Canagliflozin protects  Heart and Kidneys &#8211; CREDENCE Trial"},"content":{"rendered":"<h1><span style=\"color: #008000;\">Canagliflozin protects Heart and Kidneys &#8211; CREDENCE Trial<\/span><\/h1>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-29538\" src=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2019\/04\/Canagliflozin-protects-heart-and-kidneys-CREDENCE-Trial.jpg\" alt=\"\" width=\"880\" height=\"496\" \/>Canagliflozin is sodium\u2013glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus. CREDENCE Trial [1] has shown that Canagliflozin provides both cardiovascular and renal protection in patients with type 2 diabetes mellitus.<\/p>\n<p><strong><span style=\"color: #0000ff;\">CREDENCE<\/span> <\/strong>(<span style=\"color: #0000ff;\">Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation<\/span>) <span style=\"color: #0000ff;\"><strong>trial<\/strong> <\/span>was a double blind randomized trial comparing Canagliflozin 100 mg daily with placebo in type 2 diabetes with albuminuria and chronic kidney disease. They were also treated with renin\u2013angiotensin system blockade.<\/p>\n<p><span style=\"color: #ff00ff;\">They found that risk of both kidney failure and cardiovascular events were lower in canagliflozin group at a median follow-up of 2.62 years.<\/span><\/p>\n<p>Renal specific composite end point was end-stage kidney disease, doubling of serum creatinine level or death from renal cause. Relative risk of the composite end point was lower by 34% (P&lt;0.001) in the canagliflozin group. Relative risk of end-stage renal disease was lower by 32% (P=0.002).<\/p>\n<p>There was a lower risk of cardiovascular death, myocardial infarction, or stroke (P=0.01). Risk of hospitalization for heart failure was also lower (P&lt;0.001).<\/p>\n<p><span style=\"color: #008000;\">Interestingly there was no increase in the rates of rates of amputation or fracture in the study group<\/span>. An important concern raised in the CANVAS program (Canagliflozin Cardiovascular Assessment Study) for Canagliflozin was a potential risk of higher rates of amputation, primarily at the level of the toe or metatarsal [2].<\/p>\n<h2><span style=\"color: #0000ff;\">Reference<\/span><\/h2>\n<ol>\n<li>Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris GL, Bull S, Cannon CP,\u00a0 Capuano G, Chu P, de Zeeuw D, Greene T,\u00a0 Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; for the CREDENCE Trial Investigators. <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1811744\">Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy<\/a>. N Engl J Med. April 14, 2019. DOI: 10.1056\/NEJMoa1811744<\/li>\n<li>Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Canagliflozin protects Heart and Kidneys &#8211; CREDENCE Trial Canagliflozin is sodium\u2013glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus. CREDENCE Trial [1] has shown that Canagliflozin provides both cardiovascular and renal protection in patients with type 2 diabetes mellitus. CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":29538,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[2],"tags":[],"class_list":["post-29537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cardiology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Canagliflozin protects Heart and Kidneys - CREDENCE Trial - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Canagliflozin protects Heart and Kidneys - CREDENCE Trial - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Canagliflozin protects Heart and Kidneys &#8211; CREDENCE Trial Canagliflozin is sodium\u2013glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus. CREDENCE Trial [1] has shown that Canagliflozin provides both cardiovascular and renal protection in patients with type 2 diabetes mellitus. CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-15T16:26:38+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Canagliflozin protects Heart and Kidneys &#8211; CREDENCE Trial\",\"datePublished\":\"2019-04-15T16:26:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/\"},\"wordCount\":344,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"Cardiology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/\",\"name\":\"Canagliflozin protects Heart and Kidneys - CREDENCE Trial - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2019-04-15T16:26:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/canagliflozin-protects-heart-and-kidneys-credence-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Canagliflozin protects Heart and Kidneys &#8211; CREDENCE Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Canagliflozin protects Heart and Kidneys - CREDENCE Trial - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/","og_locale":"en_US","og_type":"article","og_title":"Canagliflozin protects Heart and Kidneys - CREDENCE Trial - All About Cardiovascular System and Disorders","og_description":"Canagliflozin protects Heart and Kidneys &#8211; CREDENCE Trial Canagliflozin is sodium\u2013glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus. CREDENCE Trial [1] has shown that Canagliflozin provides both cardiovascular and renal protection in patients with type 2 diabetes mellitus. CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2019-04-15T16:26:38+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Canagliflozin protects Heart and Kidneys &#8211; CREDENCE Trial","datePublished":"2019-04-15T16:26:38+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/"},"wordCount":344,"commentCount":0,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/#primaryimage"},"thumbnailUrl":"","articleSection":["Cardiology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/","url":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/","name":"Canagliflozin protects Heart and Kidneys - CREDENCE Trial - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/#primaryimage"},"thumbnailUrl":"","datePublished":"2019-04-15T16:26:38+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/canagliflozin-protects-heart-and-kidneys-credence-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Canagliflozin protects Heart and Kidneys &#8211; CREDENCE Trial"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/29537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=29537"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/29537\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=29537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=29537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=29537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}